R&D-Driven Growth RAFARM invests a significant share of net turnover into research and development, maintains a robust pipeline with over 100 development products, and advances multiple new products annually. Opportunity: partner on sterile and ophthalmic product development, co-create innovative formulations, and access ongoing pipeline for long-term collaboration.

Global Expansion With exports to more than 60 countries and a growing domestic market presence, RAFARM seeks international partnerships to broaden distribution, leverage its accessory production capabilities, and facilitate regulatory support for market entry in new regions.

Ophthalmic & Injectable Focus Specialization in ophthalmic and sterile injectable products highlights a niche expertise that can be leveraged for contract manufacturing, fill-finish services, and joint development of advanced ocular therapies for global markets.

Manufacturing Scale Three production units, an in-house R&D center, and substantial investment plans indicate capacity to support large or multi-country launch programs. Potential sales opportunities include contract manufacturing, licensing deals, and technology transfer agreements.

Strategic Partnerships Past collaboration with Padagis, Upsher-Smith, Modern Retina, and Ophthalmology Times suggests openness to co-development and distribution partnerships. Approach: propose joint ventures, co-marketing, or exclusive distribution arrangements in select territories.